GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » EV-to-FCF

ESLA (Estrella Immunopharma) EV-to-FCF : -0.48 (As of Oct. 31, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Estrella Immunopharma's Enterprise Value is $7.64 Mil. Estrella Immunopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was $-16.07 Mil. Therefore, Estrella Immunopharma's EV-to-FCF for today is -0.48.

The historical rank and industry rank for Estrella Immunopharma's EV-to-FCF or its related term are showing as below:

ESLA' s EV-to-FCF Range Over the Past 10 Years
Min: -119.45   Med: 0   Max: 0
Current: -0.48

ESLA's EV-to-FCF is ranked worse than
100% of 372 companies
in the Biotechnology industry
Industry Median: 7.88 vs ESLA: -0.48

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-10-31), Estrella Immunopharma's stock price is $0.761. Estrella Immunopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.223. Therefore, Estrella Immunopharma's PE Ratio (TTM) for today is At Loss.


Estrella Immunopharma EV-to-FCF Historical Data

The historical data trend for Estrella Immunopharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma EV-to-FCF Chart

Estrella Immunopharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24
EV-to-FCF
- - - -2.11

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -2.57 -2.56 -2.11

Competitive Comparison of Estrella Immunopharma's EV-to-FCF

For the Biotechnology subindustry, Estrella Immunopharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Estrella Immunopharma's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Estrella Immunopharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Estrella Immunopharma's EV-to-FCF falls into.



Estrella Immunopharma EV-to-FCF Calculation

Estrella Immunopharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=7.643/-16.069
=-0.48

Estrella Immunopharma's current Enterprise Value is $7.64 Mil.
Estrella Immunopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Estrella Immunopharma  (NAS:ESLA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Estrella Immunopharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.761/-0.223
=At Loss

Estrella Immunopharma's share price for today is $0.761.
Estrella Immunopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.223.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Estrella Immunopharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Estrella Immunopharma Business Description

Traded in Other Exchanges
N/A
Address
5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma Headlines